Navigation Links
Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
Date:8/7/2008

SAN RAMON, Calif., Aug. 7 /PRNewswire/ -- Odyssey Thera, Inc. announced that it has received a milestone payment from Pfizer Inc, following Pfizer's decision to progress a discovery stage drug candidate into pre-clinical development. The drug candidate was extensively studied by Odyssey Thera as part of the ongoing collaboration with Pfizer.

"We are very pleased with the progress of the collaboration with Pfizer," said John K. Westwick, Ph.D., Odyssey Thera's President and CEO. "Progress on this and other discovery programs with Pfizer demonstrates the power of our unique cellular analysis platform to improve knowledge of drug mechanisms and selectivity."

In August 2006, Odyssey Thera announced its third alliance with Pfizer. Under the terms of the multi-year agreement, Odyssey Thera is collaborating on multiple Pfizer drug discovery projects, and has received upfront payments, research and capital expenditure funding, and previous success-based milestones. The achievement of this milestone announced today is the Company's first such milestone to be earned for contributing to the advancement of a drug candidate.

About Odyssey Thera, Inc.

Odyssey Thera's patented technology measures disease-relevant pathway activity within living human cells. Rapid identification of on-target and off-pathway activities of lead compounds enables selection of drug candidates with favorable safety and selectivity profiles. Odyssey is leveraging its proprietary drug discovery and development platform for internal programs and for premier pharmaceutical company partners.

To learn more about Odyssey Thera, please visit http://www.odysseythera.com


'/>"/>
SOURCE Odyssey Thera, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Stereotaxis Highlights a Transatlantic Arrhythmia Procedure Collaboration With the Odyssey(TM) Network
2. Odyssey Thera Granted U.S. Patent for Animal Imaging
3. Orexigen(R) Therapeutics Schedules Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2008
4. IBC Life Sciences Kicks Off the 13th Annual Drug Discovery & Development of Innovative Therapeutics World Congress in Boston, Massachusetts
5. VIA Pharmaceuticals to Present at 13th Annual IBC Life Sciences Drug Discovery & Development of Innovative Therapeutics World Congress
6. CV Therapeutics Reports 2008 Second Quarter Financial Results
7. Horizon Therapeutics Announces Corporate Relocation to the Chicago Area
8. Amicus Therapeutics Announces Second Quarter 2008 Results Release Date
9. Cardinal Health, Prime Therapeutics Sign Primary Distribution Agreement
10. United Therapeutics Reports Second Quarter 2008 Financial Results
11. Silence Therapeutics Receives Allowance from United States Patent and Trademark Office for its Core RNAi Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/15/2017)... ... May 15, 2017 , ... Continuing to build off ... has today launched its first-ever cross-medium campaign, #StandFirm, with high-visibility social and digital ... social media channels, emphasizing Algenist’s stance on individuality and disruption: , We ...
(Date:5/12/2017)... ARBOR, Mich. , May 12, 2017 ... selected to present at the 36th annual Michigan Growth ... Forum. GreenMark, a Delaware corporation ... be presenting to investors in attendance, including more than ... deliver health benefits to society through biobased targeting technologies. ...
(Date:5/11/2017)... BioLife Solutions , Inc. (NASDAQ: BLFS ), a ... and tissue hypothermic storage and cryopreservation freeze ... and financial results for the first quarter of 2017. ... high of $2.4 million in the first quarter of 2017, ... Revenue growth was driven by sales of CryoStor ® ...
(Date:5/11/2017)... Yorba Linda, Ca (PRWEB) , ... May 11, ... ... (hPSCs) and primary rodent neurons both are excellent resources for disease modeling and ... culture and further differentiated into mature neurons for various applications, however, these often ...
Breaking Biology Technology:
(Date:3/29/2017)... 29, 2017  higi, the health IT company that ... North America , today announced a Series B ... of EveryMove. The new investment and acquisition accelerates higi,s ... to transform population health activities through the collection and ... higi collects and secures data today on behalf ...
(Date:3/24/2017)... The Controller General of Immigration from Maldives Mr. Mohamed ... received the prestigious international IAIR Award for the most innovative high security ... ... Maldives Immigration Controller General, ... picture on the right) have received the IAIR award for the "Most ...
(Date:3/23/2017)... , Mar. 23, 2017 Research and Markets ... Market Analysis & Trends - Industry Forecast to 2025" report ... ... at a CAGR of around 8.8% over the next decade to ... report analyzes the market estimates and forecasts for all the given ...
Breaking Biology News(10 mins):